drugset
drugset / Trial / NCT03130634

The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment

NCT03130634 ↗

Phase 4 Completed 70 enrolled Kaohsiung Medical University Chung-Ho Memorial Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Primary objectives: Use both listed and relatively safe drug, Silymarin,s to improve the intestinal side effect of the patients undergoing FOLFIRI chemotherapy.

Timeline

Start
2016-04
Primary completion
2019-06
Completion
2020-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Silymarin Traditional medicine (herbal / TCM) 150 mg —

Indications

colorectal cancer